ERYTECH announces enrollment of first patient in Phase I/II study of eryaspase in Acute Lymphoblastic Leukemia in the United States

Post author:admERY
Post published:July 22, 2014
Post category:Newsroom

ERYTECH announces the enrollment of the first patient in its Phase I/II study with eryaspase in Acute Lymphoblastic Leukemia in the United States of America.

You Might Also Like

ERYTECH Provides Business and Financial Highlights for First Quarter 2016

ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update

ERYTECH to Present Full Results for Phase 2b Trial of eryaspase in Pancreatic Cancer at ESMO 2017